- Fee assured
- Verified this account
You'll need to contact this healthcare professional to check their availability
Dr Toby Eyre is a consultant haematologist at Oxford University Hospitals NHS Foundation Trust, specialising in the management of lymphoid malignancies. He is considered a national expert in the management of patients with lymphoma and patients with chronic lymphocytic leukaemia.
Toby has completed an MD Doctorate Thesis in early phase trials and biomarker studies in aggressive lymphoid disease in 2017. He completed his haematology training in the Oxford deanery between 2010 and 2017.
Toby is an investigator on a number of national UK lymphoma and chronic lymphocytic leukaemia trials and has published nearly 70 peer-review articles on areas of lymphoma and CLL and has presented regularly at national and international conferences. He is also a core member of the low grade lymphoma and elderly high grade lymphoma NCRI clinical studies group and a member of the BSCH guideline writing group for follicular lymphoma and post-transplantation lymphoproliferative disorders.
Toby has a strong interest in teaching and training and has completed a post-graduate Diploma in Medical Education.
Areas of interest
Lymphoma; CLL; Haematology; Chronic Lymphocytic Leukaemia; haemato-oncology, lymphoid malignancies; Hodgkins Lymphoma; Non-Hodgkins Lymphoma; Clinical trials; immunotherapy; chemotherapy
Current NHS consultant posts held
Oxford University Hospitals NHS Foundation Trust
Early and late phase clinical trials
Real world clinical outcomes analysis
Areas of focus: Elderly DLBCL, CLL, low grade lymphoma including follicular lymphoma and mantle cell lymphoma
Gardening, Cricket, Rugby
Prognostication in Richter syndrome: context is everything.
Eyre TA.Br J Haematol. 2020 May 18. doi: 10.1111/bjh.16757. Online ahead of print. PMID: 32420622 No abstract available.
DPACE-based chemotherapy in the era of myeloma novel agents: a UK multicentre study.
Djebbari F, De Abrew K, Salhan B, Panitsas F, Hossain MI, Eyre TA, Willan J, Ramasamy K, Basu S, Jenner M, Kothari J. Eur J Haematol. 2020 Apr 8. doi: 10.1111/ejh.13422. [Epub ahead of print]
Outcomes of older patients with primary central nervous system lymphoma treated in routine clinical practice in the UK: methotrexate dose intensity correlates with response and survival.
Martinez-Calle N, Poynton E, Alchawaf A, Kassam S, Horan M, Rafferty M, Kelsey P, Scott G, Culligan DJ, Buckley H, Lim YY, Ngu L, McCulloch R, Rowntree C, Wright J, McKay P, Fourali S, Eyre TA, Smith J, Osborne W, Yallop D, Linton K, Fox CP, Cwynarski K. Br J Haematol. 2020 Mar 31. doi: 10.1111/bjh.16592. [Epub ahead of print]
Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK inhibition as an Effective Strategy.
Mato AR, Roeker LE, Jacobs R, Hill BT, Lamanna N, Brander D, Shadman M, Ujjani CS, Sarraf Yazdy M, Perini GF, Pinilla-Ibarz JA, Barrientos J, Skarbnik AP, Torka P, Pu JJ, Pagel JM, Gohil S, Fakhri B, Choi M, Coombs CC, Rhodes J, Barr PM, Portell CA, Parry H, Garcia CA, Whitaker KJ, Winter AM, Sitlinger A, Khajavian S, Grajales-Cruz AF, Isaac KM, Shah P, Akhtar OS, Pocock R, Lam K, Voorhees TJ, Schuster SJ, Rodgers TD, Fox CP, Martinez-Calle N, Munir T, Bhavsar EB, Bailey N, Lee JC, Weissbrot HB, Nabhan C, Goodfriend JM, King AC, Zelenetz AD, Dorsey C, Bigelow K, Cheson BD, Allan JN, Eyre TA. Clin Cancer Res. 2020 Mar 20. pii: clincanres.3815.2019. doi: 10.1158/1078-0432.CCR-19-3815. [Epub ahead of print]
- MBChB (Hons) University of Bristol 2006
- Diploma in Medical Education (PGDip) UK 2010
- MRCP (UK) UK 2008
- FRCPath UK 2015
- Doctorate of Medicine Newcastle University 2017
Reference number 6145730
Affiliations / memberships
British society of haematology